These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37682096)

  • 1. [Experience of using a Russian alteplase product as thrombolytic therapy in patients with ischemic stroke in routine practice].
    Murtazalieva DM; Zakaryaeva AR; Soshina TD; Zolotov MA; Parfenov VA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(8. Vyp. 2):55-59. PubMed ID: 37682096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intravenous thrombolytic therapy of ischemic stroke with the drug Revelisa in real clinical practice: results of the IVT-AIS-R study].
    Soldatov MA; Klimov LV; Tolmachev AP; Kiseleva TV; Androfagina OV; Beketova EM; Belkina SN; Borisov DN; Karpov DY; Krasyuk MS; Kucheryavaya MV; Minina YD; Novikov DG; Rogozhnikova NV; Tabakman SV; Teliatnik YA; Tretyakov KV; Fadeeva AS; Khan DS; Chirkov AN; Marskaya NA; Shamalov NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(12. Vyp. 2):42-49. PubMed ID: 36582160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intravenous thrombolytic therapy with Revelisa of ischemic stroke in real-world clinical practice: interim results of an open-label, prospective, multicenter, non-interventional study IVT-AIS-R].
    Soldatov MA; Marskaya NA; Barsegova KA; Androfagina OV; Borisov DN; Karpov DY; Kishinevsky MV; Kucheryavaya MV; Tabakman SV; Telyatnik YA; Fadeeva AS; Khan DS; Chirkov AN; Shamalov NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(3. Vyp. 2):33-37. PubMed ID: 33908230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intravenous thrombolysis in acute ischemic stroke patients with cerebral microbleeds and analysis of risk factors for hemorrhagic transformation.
    Lei YS; Li H; Lei JY; Li SX; Li DF
    Eur Rev Med Pharmacol Sci; 2022 Feb; 26(3):779-786. PubMed ID: 35179744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Independence of ischemic stroke patients after alteplase systemic thrombolytic therapy].
    Belkina SN; Kotov SV; Isakova EV; Kotov AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(12. Vyp. 2):56-61. PubMed ID: 35044127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase II trial.
    van der Ende NAM; Roozenbeek B; Smagge LEM; Luijten SPR; Aerden LAM; Kraayeveld P; van den Wijngaard IR; Lycklama À Nijeholt GJ; den Hertog HM; Flach HZ; Wallace AC; Gurewich V; Del Zoppo GJ; Meurer WJ; Lingsma HF; van der Lugt A; Dippel DWJ;
    Trials; 2022 Aug; 23(1):641. PubMed ID: 35945566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative characteristics of the efficacy and safety of the original alteplase and its complete biosimilar in the treatment of ischemic stroke in real clinical practice].
    Marchenko SV; Hil UV; Hil IG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(3. Vyp. 2):49-54. PubMed ID: 38512095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances.
    Alper BS; Foster G; Thabane L; Rae-Grant A; Malone-Moses M; Manheimer E
    BMJ Evid Based Med; 2020 Oct; 25(5):168-171. PubMed ID: 32430395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of thrombolytic therapy of ischemic stroke in the Russian Federation].
    Skvortsova VI; Shamalov NA; Anisimov KV; Ramazanov GR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12 Pt 2):17-22. PubMed ID: 21630489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new nomogram for individualized prediction of the probability of hemorrhagic transformation after intravenous thrombolysis for ischemic stroke patients.
    Wu Y; Chen H; Liu X; Cai X; Kong Y; Wang H; Zhou Y; Zhu J; Zhang L; Fang Q; Li T
    BMC Neurol; 2020 Nov; 20(1):426. PubMed ID: 33234113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits ECASS-4: ExTEND.
    Amiri H; Bluhmki E; Bendszus M; Eschenfelder CC; Donnan GA; Leys D; Molina C; Ringleb PA; Schellinger PD; Schwab S; Toni D; Wahlgren N; Hacke W
    Int J Stroke; 2016 Feb; 11(2):260-7. PubMed ID: 26783318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
    Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
    Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rt-PA thrombolytic therapy in patients with acute posterior circulation stroke: A retrospective study.
    Hu Y; Zheng H; Chen X; Gao Z
    Med Int (Lond); 2022; 2(2):8. PubMed ID: 36699100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
    Schwammenthal Y; Drescher MJ; Merzeliak O; Tsabari R; Bruk B; Feibel M; Hoffman C; Bakon M; Rotstein Z; Chapman J; Tanne D
    Isr Med Assoc J; 2004 Feb; 6(2):70-4. PubMed ID: 14986460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of atrial fibrillation on clinical outcome in patients with acute ischemic stroke undergoing thrombolytic therapy].
    Lou YP; Yan SQ; Zhang S; Chen ZC; Wan JP; Lou M
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jan; 43(1):28-35. PubMed ID: 24616458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy.
    Kikule I; Baborikina A; Haritoncenko I; Karelis G
    Medicina (Kaunas); 2022 Sep; 58(10):. PubMed ID: 36295516
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).
    Hacke W; Kaste M; Fieschi C; Toni D; Lesaffre E; von Kummer R; Boysen G; Bluhmki E; Höxter G; Mahagne MH
    JAMA; 1995 Oct; 274(13):1017-25. PubMed ID: 7563451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.